**Supplementary Table S4. Sensitivity and specificity of AFP cutoffs in differentiating patients by response status per IRF-assessed RECIST 1.1.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Point estimate (95% CI) | RECIST 1.1  (n = 144) | | | |
| ≥20% AFP decrease  (responders vs  non-responders) | ≥50% AFP decrease  (responders vs  non-responders) | ≥20% AFP decrease  (disease control vs primary progressors) | ≥50% AFP decrease  (disease control vs primary progressors) |
| Sensitivity | 0.79  (0.64–0.91) | 0.64  (0.47–0.79) | 0.62  (0.52–0.71) | 0.41  (0.32–0.51) |
| Specificity | 0.54  (0.44–0.64) | 0.74  (0.65–0.82) | 0.68  (0.49–0.83) | 0.79  (0.62–0.91) |
| Positive predictive value | 0.39  (0.28–0.51) | 0.48  (0.34–0.62) | 0.86  (0.76–0.93) | 0.87  (0.74–0.94) |
| Negative predictive value | 0.88  (0.77–0.95) | 0.85  (0.76–0.91) | 0.35  (0.24–0.48) | 0.29  (0.20–0.40) |
| AFP, alpha-fetoprotein; IRF, independent review facility; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1. | | | | |